VP decreases the pool of CD44+ ALDH+ CSCs and the expression of several CSC markers in GC, thereby affecting GC cells tumoursphere-forming capacity and proliferation in vitro as well as tumour initiation and growth in PDX models in vivo. The gene discussed is CD44; the disease is gastric cancer.